WP 631 and Epo B synergize in SKOV-3 human ovarian cancer cells

Environmental Toxicology and Pharmacology

Volumn 37, Issue 1, 2014, Pages 256-266

  Marczak, Agnieszka ^a   Bukowska, Barbara ^a   Rogalska, Aneta ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Epothilone B; Isobolograms; Ovarian cancer; Synergism; WP 631

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3',3' N XYLENYLBIS(DAUNORUBICIN); 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; EPOTHILONE B; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; PROPIDIUM IODIDE;

ANALYTIC METHOD; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL STRAIN SKOV 3; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; IMMUNOCYTOCHEMISTRY; ISOBOLOGRAPHIC ANALYSIS; NICK END LABELING; OVARY CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT DURATION;

APOPTOSIS; EPOTHILONE B; ISOBOLOGRAMS; OVARIAN CANCER; SYNERGISM; WP 631;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DAUNORUBICIN; DRUG SYNERGISM; EPOTHILONES; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84890955992     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2013.12.002     Document Type: Article

References (38)

1. Ashikawa K., Shishodia S., Fokt I., Priebe W., Aggarwal B.B. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem. Pharmacol. 2004, 67(2):353-364.
2. Bourgeois H., Ferru A., Lortholary A., Delozier T., Boisdron-Celle M., Abadie-Lacourtoisie S., Joly F., Chieze S., Chabrun V., Gamelin E., Tourani J.M. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer. Am. J. Clin. Oncol. 2006, 29(3):267-275.
3. Brooks T.A., O'Loughlin K.L., Minderman H., Bundy B.N., Ford L.A., Vredenburg M.R., Bernacki R.J., Priebe W., Baer M.R. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Invest. New Drugs 2007, 25(2):115-122.
4. Brüning A., Mylonas I. New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer. Arch. Gynecol. Obstet. 2011, 283(5):1087-1096.
5. Campos S.M., Matulonis U.A., Penson R.T., Lee H., Berkowitz R.S., Duska L.R., Fuller A.F., Wilson K.S., Puchalski T.A., Supko J.G., Seiden M.V. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. Gynecol. Oncol. 2003, 90(3):610-618.
6. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47(4):936-942.
7. Chaires J.B., Leng F., Przewloka T., Fokt I., Ling Y.H., Perez-Soler R., Priebe W. Structure-based design of a new bisintercalating anthracycline antibiotic. J. Med. Chem. 1997, 40(3):261-266.
8. Cheng K.L., Bradley T., Budman D.R. Novel microtubule-targeting agents - the epothilones. Biologics 2008, 2(4):789-811.
9. Cocco R.E., Ucker D.S. Distinct modes of macrophage recognition for apoptotic and necrotic cells are not specified exclusively by phosphatidylserine exposure. Mol. Biol. Cell 2001, 12(4):919-930.
10. Duska L.R., Penson R., Supko J., Finkelstein D.M., Makastorsis T., Gallagher J., Borden K., Goodman A., Fuller A.F., Nikrui N., Seiden M.V. A phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. Clin. Cancer Res. 1999, 5(6):1299-1305.
11. Gan L., Wang J., Xu H., Yang X. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate 2011, 71(11):1158-1166.
12. Gasiorowski K., Brokos B., Kulma A., Ogorzałek A., Skórkowska K. A comparison of the methods applied to detect apoptosis in genotoxically-damaged lymphocytes cultured in the presence of four antimutagens. Cell. Mol. Biol. Lett. 2001, 6(2):141-159.
13. Gehl J., Boesgaard M., Paaske T., Vittrup Jensen B., Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann. Oncol. 1996, 7(7):687-693.
14. Gessner P.K. Isobolographic analysis of interactions: an update on applications and utility. Toxicology 1995, 105:161-179.
15. Gonzalez-Sanchez I., Lira-Rocha A., Navarrete A., Loza-Mejía M.A., Coronel-Cruz C., Mendoza-Rodríguez C.A., Cerbón M.A. Synergistic anticancer activity of thiazolo[5,4-b]quinoline derivative D3CLP in combination with cisplatin in human cervical cancer cells. Anticancer Res. 2012, 32(12):5159-5165.
16. Haj H.T., Salerno M., Priebe W., Kozlowski H., Garnier-Suillerot A. New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA. Chem. Biol. Interact. 2003, 145(3):349-358.
17. Hong R.L., Lin C.H., Chao T.Y., Kao W.Y., Wang C.H., Hsieh R.K., Hwang W.S. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline. Cancer Chemother. Pharmacol. 2008, 61(5):847-853.
18. Jin C., Li H., He Y., He M., Bai L., Cao Y., Song W., Dou K. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J. Cancer Res. Clin. Oncol. 2010, 136(2):267-274.
19. Kim A., Ueda Y., Naka T., Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J. Exp. Clin. Cancer Res. 2012, 31:14. 10.1186/1756-9966-31-14.
20. Koceva-Chyła A., Jedrzejczak M., Skierski J., Kania K., Jóźwiak Z. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. Apoptosis 2005, 10(6):1497-1514.
21. Kumar A., Heise H., Blommers M.J., Krastel P., Schmitt E., Petersen F., Jeganathan S., Mandelkow E.M., Carlomagno T., Griesinger C., Baldus M. Interaction of epothilone B (patupilone) with microtubules as detected by two-dimensional solid-state NMR spectroscopy. Angew. Chem. Int. Ed. Engl. 2010, 49(41):7504-7507.
22. Lee F.Y., Smykla R., Johnston K., Menard K., McGlinchey K., Peterson R.W., Wiebesiek A., Vite G., Fairchild C.R., Kramer R. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother. Pharmacol. 2009, 63(2):201-212.
23. Li W., Zhai L., Tang Y., Cai J., Liu M., Zhang J. Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo. Oncol. Res. 2012, 20:49-59.
24. Loewe S. Die Mischiarnei. Klin. Wochenschr. 1927, 6:1077-1085.
25. Loewe S. Die quantitativen probleme der pharmakologie. Ergeb. Physiol. 1928, 27:47-187.
26. Mansilla S., Bataller M., Portugal J. A nuclear budding mechanism in transiently arrested cells generates drug-sensitive and drug-resistant cells. Biochem. Pharmacol. 2009, 78(2):123-132.
27. Morgan S., Lopes F., Gourley C., Anderson R.A., Spears N. Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PLoS ONE 2013, 8:e70117.
28. Rogalska A., Gajek A., Szwed M., Jóźwiak Z., Marczak A. The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of doxorubicin. Toxicol. In Vitro 2011, 25(8):1712-1720.
29. Rogalska A., Szwed M., Jóźwiak Z. Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours. Mutat. Res. 2010, 700:1-10.
30. Rogalska A., Marczak A., Gajek A., Szwed M., Śliwińska A., Drzewoski J., Jóźwiak Z. Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B. Toxicol. In Vitro 2013, 27(1):239-249.
31. Safdie F.M., Dorff T., Quinn D., Fontana L., Wei M., Lee C., Cohen P., Longo V.D. Fasting and cancer treatment in humans: a case series report. Aging 2009, 1(12):988-1007.
32. Tallarida R.J. Drug Synergism and Dose-Effect Data Analysis 2000, Boca Raton Chapman & Hall/CRC, Florida, USA.
33. Tallarida R.J. Interactions between drugs and occupied receptors. Pharmacol. Ther. 2007, 113(1):197-209.
34. Tallarida R.J., Raffa R.B. Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram. Life Sci. 1996, 58(2):23-28.
35. Villamarin S., Ferrer-Miralles N., Mansilla S., Priebe W., Portugal J. Induction of G(2)/M arrest and inhibition of c-myc and p53 transcription by WP 631 in Jurkat T lymphocytes. Biochem. Pharmacol. 2002, 63(7):1251-1258.
36. Villar V.H., Vogler O., Martinez-Serra J., Ramos R., Calabuig-Fariñas S., Gutiérrez A., Barceló F., Martín-Broto J., Alemany R. Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas. PLoS ONE 2012, 7(5):e37735.
37. Zhao Y., Fang W.S., Pors K. Microtubule stabilising agents for cancer chemotherapy. Expert Opin. Ther. Pat. 2009, 19(5):607-622.
38. Zwaal R.F., Comfurius P., Bevers E.M. Surface exposure of phosphatidylserine in pathological cells. Cell. Mol. Life Sci. 2005, 62(9):971-988.